NYU Lung Cancer Biomarker Center
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- NYU Langone Health
- Enrollment
- 10850
- Locations
- 1
- Primary Endpoint
- Lung cancer diagnosis as measured by CT scan findings and pathology findings annually
- Status
- Recruiting
- Last Updated
- 10 months ago
Overview
Brief Summary
RATIONALE: Screening tests that use biomarkers may help doctors find tumor cells early and plan effective treatment for lung cancer.
PURPOSE: This clinical trial is studying biomarkers in screening participants for lung cancer.
Detailed Description
OBJECTIVES: * Identify and validate biomarkers for the early detection of lung cancer in individuals at low- or high-risk for smoking-related cancers. * Identify preneoplastic cellular changes and lesions in these patients. OUTLINE: Participants are stratified according to lung cancer risk status (with or without increased risk). Group 1 (screening cohort): Participants complete a questionnaire and undergo pulmonary function testing, multidetector chest CT scan, sputum induction, and phlebotomy. Group 2 (rule-out lung cancer): Participants complete the same questionnaire and undergo the same tests and scans as in group 1. Some participants may undergo fiberoptic bronchoscopy based upon CT scan results with transbronchial or endobronchial biopsies. Some participants may undergo lung resection. Tissue samples are collected from surgery or biopsy. PROJECTED ACCRUAL: A total of participants will be accrued for this study.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Lung cancer diagnosis as measured by CT scan findings and pathology findings annually
Time Frame: 07/01/2015
Secondary Outcomes
- Precancerous lung nodules as measured by CT scan findings and pathology findings annually(07/01/2015)